Grace Therapeutics
GRCE
27 hedge funds and large institutions have $6.67M invested in Grace Therapeutics in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
129% more capital invested
Capital invested by funds: $2.92M → $6.67M (+$3.76M)
108% more funds holding
Funds holding: 13 → 27 (+14)
0.02% more ownership
Funds ownership: 0.07% → 0.09% (+0.02%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Peconic Partners
New York
|
+$675K |
| 2 |
Two Sigma Advisers
New York
|
+$660K |
| 3 |
Renaissance Technologies
New York
|
+$484K |
| 4 |
MFS
Monetta Financial Services
Wheaton,
Illinois
|
+$193K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$380K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$74.8K |
| 3 |
Morgan Stanley
New York
|
-$68.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$17.4K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RE
26
RBC Europe
London,
United Kingdom
| $57 | – | – | – |
|
|
PVI
27
Pura Vida Investments
New York
| – | -$380K | -6,940 | Closed |
|
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$7K | -130 | Closed |
|
29
Wells Fargo
San Francisco,
California
| – | -$1K | -21 | Closed |
|
30
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$185 | +2 | New |
|
GRCE Hedge Fund Activity: Q3 2019 in Review
27 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2019, worth a combined $6.67M — up 129% from $2.92M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GRCE positions and 3 closed out — a net gain of 14 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Peconic Partners, opening a new position worth an estimated $675K. The largest seller was Pura Vida Investments, exiting entirely with an estimated $380K sold.
- 27 institutional investors held Grace Therapeutics (GRCE) as of Q3 2019, up from 13 in Q2 2019.
- Funds reported $6.67M of Grace Therapeutics stock for Q3 2019, up 129% quarter-over-quarter.
- 17 funds opened new Grace Therapeutics positions in Q3 2019 and 3 closed out, a net change of +14 holders.
- The largest Grace Therapeutics buyer in Q3 2019 was Peconic Partners, an estimated $675K added.
- The largest Grace Therapeutics seller in Q3 2019 was Pura Vida Investments, an estimated $380K sold.
Based on aggregated 13F filings for Q3 2019.